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Transcription factorOver the last decade, there has been a growing interest in the use of interventions that target the intestinal mi-
crobiota as a treatment approach for asthma. This study is aimed at exploring the therapeutic effects of long-
term treatment with a combination of Biﬁdobacterium brevewith non-digestible oligosaccharides on airway in-
ﬂammation and remodeling. A murine ovalbumin-induced chronic asthma model was used. Pulmonary airway
inﬂammation;mRNA expression of pattern recognition receptors, Th-speciﬁc cytokines and transcription factors
in lung tissue; expression of Foxp3 in blood Th cells; in vitro T cell activation;mast cell degranulation; and airway
remodeling were examined. The combination of B. breve with non-digestible oligosaccharides suppressed pul-
monary airway inﬂammation; reduced T cell activation and mast cell degranulation; modulated expression of
pattern recognition receptors, cytokines and transcription factors; and reduced airway remodeling. The treat-
ment induced regulatory T cell responses, as shown by increased Il10 and Foxp3 transcription in lung tissue,
and augmented Foxp3 protein expression in blood CD4+CD25+Foxp3+ T cells. This speciﬁc combination of
beneﬁcial bacteria with non-digestible oligosaccharides has strong anti-inﬂammatory properties, possibly via
the induction of a regulatory T cell response, resulting in reduced airway remodeling and, therefore, may be ben-
eﬁcial in the treatment of chronic inﬂammation in allergic asthma.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Allergic asthma is a T helper type-2 (Th2) cell-mediated chronic in-
ﬂammatory disorder of the airways characterized by airway inﬂamma-
tion and hyper-responsiveness [1]. Persistent chronic inﬂammation and
subsequent inadequate repair of injured tissue can result in structural
changes in the airwaywalls of asthmatic patients, referred to as “airway
remodeling” [2]. Airway remodeling is thought to be caused by an im-
balance in regeneration and repair mechanisms leading to a disequilib-
rium between the synthesis and degradation of the extra-cellular
matrix components [1] and characteristic thickening of the airway
wall, increased smooth muscle mass, and vascularity and epithelial ab-
normalities [3]. The combination of these processes causes airway
narrowing and reduced lung function [1,3]. Activation of mast cells in-
duces degranulation and release of various inﬂammatory substances,ology, Utrecht Institute for
versity, PO Box 80082, 3508 TB
ights reserved.including proteases [4]. Proteases are important regulators of mast cell
function and mouse mast cell protease 1 (mMCP-1) has been shown
to enhance airway narrowing in mice [5,6]. Additionally, eosinophils
and neutrophils play key roles in the cellular airway inﬂammation [7].
The incidence and prevalence of allergic asthma are rapidly increas-
ing throughout the world, especially in children and within developing
countries. To date, the underlying immunological processes of asthma
are still not fully understood as it is a complex multifactorial disorder
in which both innate and adaptive immune responses are involved [8].
Although the majority of asthma patients is well controlled with in-
haled corticosteroids with or without long-acting β2-agonists, over 50%
of asthmatics are poorly controlled largely due to poor adherence [9]. In
addition, β2-agonists are aimed at relieving the symptoms rather than
treatment of the disease, and long-term corticosteroid therapy has un-
desirable side effects [10]. These limitations of the current treatments
for asthma highlight the need for novel therapeutics targeting underly-
ing allergic and immune responses with greater disease control, in-
creased efﬁcacy and a major clinical effect. Animal models for allergic
asthma are important for understanding of the pathophysiology under-
lying the disease. Recently, there has been a focus ondeveloping chronic
allergen exposure models, especially in mice, to reproduce more of the
clinical features of asthmatic patients, such as airway remodeling [1,11].
574 S. Sagar et al. / Biochimica et Biophysica Acta 1842 (2014) 573–583Animal studies have demonstrated a substantial inﬂuence of the gut
microbiota on immune function beyond the gut. There is now increasing
evidence that changes in the gut microbiota contribute to the develop-
ment of allergies and asthma [12–16].
Non-digestible oligosaccharides are oligosaccharides that resist
digestion but are fermentable by intestinal microbiota, such as
galacto-oligosaccharides (GOS), fructo-oligosaccharides (FOS) and
pectin-derived acidic oligosaccharides (AOS), and are thought to beme-
tabolized by or increase the survival of probiotics, “live microorganisms
which,when consumed in adequate amounts, confer a health beneﬁt on
thehost”, and speciﬁc bacterial strains in the intestinal tract [17]. A com-
bination of Biﬁdobacterium breve M-16V with a speciﬁc mixture of
short-chain GOS (sc-GOS) and long-chain FOS (lc-FOS) reduced allergic
responses in mice [18]. The same combination also proved to be useful
in patients, reducing the allergen-speciﬁc Th2-response and improving
peak expiratory ﬂow in allergic asthmatic adults, and preventing
asthma-like symptoms in infants with atopic dermatitis [19,20]. Addi-
tionally, combinations of GOS/FOS and AOS were more effective in im-
proving T helper-type 1 (Th1) immune responses and in reducing
disease parameters of allergic asthma in mice than either of the oligo-
saccharides alone [21–23].
Although the mechanism of action of these beneﬁcial bacteria still
needs to be elucidated, probiotics have been shown to contain Toll-
like receptor (TLR) ligands and can thereby modulate TLR-driven re-
sponses and skew the immune balance towards a Th1 response [24].
TLRs and NOD-like receptors (NLRs) are key pattern recognition recep-
tor (PRR) families in the innate immune response, which are also in-
volved in the activation and shaping of adaptive immunity [25]. In the
human airways, the PRRs are expressed by dendritic cells (DCs), epithe-
lial cells, eosinophils, macrophages and mast cells [26,27]. PRRs are es-
pecially crucial for modulating DC function and, ultimately, shaping
the resulting adaptive immune response [28,29]. TLR andNLR activation
in the lung also inﬂuences DCs, eosinophils and mast cells, encouraging
them to produce various chemokines and cytokines that attract activat-
ed B-lymphocytes and Th lymphocytes to the lung [30].
The function and expression of PRRs are associated with susceptibil-
ity for the development of allergic asthma in humans [31,32]. Functional
genetic variations in TLR1, TLR10 and TLR6 genes leading to increased
mRNA expression have been shown to protect against atopic asthma
in humans [32]. Genetic variations in TLR2, NOD1 and NOD2 genes that
led to either decreased mRNA expression (TLR2) or affected microbial
recognition function (NOD1 and NOD2) were positively associated
with disease susceptibility and pathogenesis [33–37]. Low TLR2, TLR4,
and TLR9 expression levels were detected in cord blood CD34(+) cells
fromhigh-atopic-risk infants. TLR9 has been demonstrated to exert pro-
tective immunomodulatory effects on asthma [38–40]. Viral activation
of Tlr3 contributed to asthma exacerbations in mice [41] and a study
in a murine macrophage cell line suggested a pro-inﬂammatory role of
Tlr4 and 5 in the disease [42].
In asthma, over 50 cytokines have now been identiﬁed that affect dis-
ease outcome. Interleukin-1β (IL-1β), IL-4, IL-5, IL-6, IL-9, IL-13, IL-17, IL-
25 and tumor necrosis factorα (TNF-α) were reported to enhance the dis-
ease. On the other hand, IL-12, IL-18 and interferon-γ (IFNγ)were reported
to reduce the symptoms of asthma in asthmatic patients [30]. Reduced
levels of the anti-inﬂammatory cytokine IL-10 were found in the sputum
of asthma patients. IL-10 is produced by alternatively activated macro-
phages and by a subset of regulatory T cells (Tregs). This cytokine exerts
its effect by inhibiting the synthesis of inﬂammatory cytokines (including
asthma-associated cytokines such as TNF-α and IL-5) and gene transcrip-
tion [43]. Th2 cells play a key role in asthma, and Th1/Th2 imbalances as
well as disturbed T helper type-17 (Th17)/Treg balances have been report-
ed in asthmatics [44]. Treg cells are important in balancing immune re-
sponses and maintaining immunological tolerance to foreign and self-
antigens, including allergens [43]. Imbalances in Th responses can also be
detected using Th-speciﬁc transcription factors: T-bet for Th1 cells, GATA-
3 for Th2 cells, retinoic acid orphan receptor-γt (RORγt) for Th17 cellsand Foxp3 for Tregs [45]. Alterations in the expression and/or function of
these transcription factors are also associated with asthma pathogenesis
[46,47].
Although the potential of beneﬁcial bacteria interventions in allergy
and related inﬂammatory conditions is becoming more evident, more
research inmice and asthma patients is needed to explore the immuno-
modulatory properties of these interventions. The aim of this current
study is to explore the therapeutic effects of long-term administration
of a combination of B. breve with non-digestible oligosaccharides on
chronic airway inﬂammation and remodeling in mice. To mimic the re-
peated allergen exposure in asthmatic patients, we used the murine
ovalbumin-induced asthma model combined with prolonged allergen
exposure. Findings from this study will contribute to a better under-
standing of the immunomodulatory and therapeutic effects of beneﬁcial
bacteria in chronic allergic asthma.
2. Material and methods
2.1. Animals
Male BALB/c mice (6–8 weeks; Charles River Laboratories, France)
were obtained and acclimated to their new environment for at least
1 week before the start of the experiment. Mice were housed under
standard conditions andhad free access to food andwater. All in vivo ex-
periments were approved by and were in accordance with the guide-
lines of the local Dutch Committee of Animal Experimentation.
2.2. Chronic asthma model
2.2.1. OVA sensitization
Sensitizations were performed on days 0 and 12. Mice were sensi-
tized to OVA (chicken egg albumin, grade V, Sigma, St. Louis, MO,
USA) by intraperitoneal injections of 0.1 mL alum-precipitated antigen,
comprising 10 μgOVA absorbed into 2.25mg alum (Imject Alum; Pierce,
Rockford, IL, USA). Control animals received 0.1 mL saline alone (NaCl
0.9%; B. Braun Medical B.V., Oss, The Netherlands) (Fig. 1).
2.2.2. OVA challenge
A chronic model of asthma was established according to a modiﬁca-
tion of a model of prolonged allergen-induced airway inﬂammation de-
scribed in [1]. Mice (OVA/OVA)were exposed daily to 5%OVA aerosol in
saline using a PARI LC Star nebulizer (PARI GmbH, Starnberg, Germany)
in an aerosol cabin for 20 min between days 17 and 23. Control animals
(OVA/Sal) were exposed to nebulized saline aerosol alone. From day 24
until day 55, the frequency of challenge was reduced to three times a
week and mice were exposed to aerosolized OVA (5%) or saline alone
for 20 min (Fig. 1).
2.3. Bb/scFOS/lsFOS/AOS treatment
The combination consisted of 109 colony forming units (CFUs) of ly-
ophilized B. breveM-16V powder with maltodextrin as carrier material
(Bb, Morinaga Milk Industry, Tokyo, Japan) combined with a speciﬁc
mixture of scFOS, lcFOS and pectin-derived acidic-oligosaccharides
(AOS). Mice (OVA/Sal–Bb/scFOS/lcFOS/AOS and OVA/OVA–Bb/scFOS/
lcFOS/AOS) received 0.2mL of themixture Bb/scFOS/lsFOS/AOS in phos-
phate buffered saline (PBS, Lonza, Leusden, TheNetherlands) by oral ga-
vage, 1 h prior to challenge, three times aweek fromday 22 until day 55.
As a negative control treatment, mice in the OVA/Sal–PBS and OVA/
OVA–PBS groups received 50 μL of PBS per day. PBS was administered
to mice by oropharyngeal aspiration after induction of light isoﬂurane
anesthesia as described previously in [48], 1 h prior to challenge, three
times a week from day 22 until day 55. Mice were rendered asthmatic
following the schema presented in Fig. 1.
Fig. 1.Time schedule of the chronic asthmamousemodel.Male BALB/cmicewere sensitized intraperitoneally to OVA-Imject Alumon days 0 and12 andmicewere challenged fromday 17
until day 23 daily with aerosolized OVA or saline. From day 22 until day 55, mice were treated 3 times a week with either PBS by oropharyngeal aspiration or Bb/scFOS/lcFOS/AOS by oral
gavage. One hour after treatment, from day 24 until day 55, mice were challenged 3 times/week with aerosolized OVA or saline. Mice were sacriﬁced on day 56.
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After sacriﬁce, on day 56, lungs were ﬁrst lavaged through a tracheal
cannula with 1 mL saline containing protease inhibitor cocktail (Com-
plete Mini, Roche Diagnostics, Mannheim, Germany), pre-warmed at
37 °C. This was followed by 3 additional lavages with 1 mL saline only.
Cytospin cell preparations were made by cytospinning the cells onto
glass for 5 min (400 g, 4 °C) and cytospins were stained by DiffQuick
(Merz & Dade AG, Düdingen, Switzerland). Numbers of eosinophils,
macrophages, neutrophils and lymphocytes were scored by light mi-
croscopy. The bronchoalveolar lavage (BAL) ﬂuid pellets were normal-
ized in unit volumes to account for differences in recovery of lavage
ﬂuid from individual mice.
2.5. RNA isolation and quantitative real-time PCR
After mice were sacriﬁced on day 56, the lungs were dissected
and mRNA was isolated from whole lung tissue. Messenger RNA iso-
lation (n = 6 mice per group) was carried out according to the
Qiagen RNeasy Mini Kit protocol (Qiagen Benelux B.V., Venlo, The
Netherlands). Reverse transcriptase PCR was performed using an
iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA,
USA). The reactions were performed in a PTC-100TM Programmable
Thermal Controller (M.J. Research, Inc., Waltham, Massachusetts,
USA) according to manufacturer's protocol.
cDNAwas ampliﬁed using iQ SYBR Green supermix in a 96-well PCR
plate and run in a CFX96 Real-Time PCR Detection System (Bio-Rad).
Primers for TLRs, NLRs, ribosomal protein S13 (RPS13, reference gene)
and T cell transcription factors were purchased by Isogen (Isogen Life
Science, De Meern, The Netherlands). The sequences are listed in Sup-
plementary Table 1. For mouse T cell cytokines, RT2 qPCR Primer Assays
(SABiosciences, Venlo, The Netherlands) were used. The protocol used
for ampliﬁcation was 94 °C for 3 min, 94 °C for 10 s, speciﬁc melt tem-
perature for 45 s, followed by 39 cycles at 94 °C for 10 s and 95 °C for
10 s.
Normalized gene expression (ΔΔCT) was calculated using the built-
in gene expression analysis module in CFX Manager™ software (CFX
Manager™ software version 1.6).
2.6. Foxp3 staining and ﬂow cytometry
On days 0 and 56, blood samples were collected frommice by cardi-
ac puncture in tubes containing lithium heparin to prevent coagulation.
The bloodwas suspended in PBS and, after centrifugation, the pelletwassubjected to red cell lysis using a buffer containingNH4Cl (Merck, Darm-
stadt, Germany), KHCO3 (Sigma), and ethylenediaminetetraacetic acid
(EDTA, Merck) in demineralized water for 5 min on ice. After several
washes with PBA (PBS containing 1% bovine serum albumin (BSA,
Roche Diagnostics, Almere, The Netherlands)) cells were resuspended
in PBA and kept on ice until Foxp3 staining.
The expression of Foxp3wasmeasured using the Foxp3 Staining Buff-
er Set (eBioscience, SanDiego, CA, USA) using the following protocol: cells
were incubated in Fixation/Permeabilizationbuffer for 30min on ice. Cells
were then washed once with PBA followed by two washes with perme-
abilization buffer. After a 15 min preincubation in total mouse serum
blocking reagent on ice, cells were washed once with permeabilization
buffer and then stained with anti-CD4 (FITC, eBioscience), anti-CD25
(PE, eBioscience) and anti-Foxp3 (APC, eBioscience) for 30 min on ice.
Cells were washed twice with permeabilization buffer and resuspended
in PBA for ﬂow cytometry analysis.
Tregs were deﬁned as CD4+Foxp3+CD25+ T cells. The stained
cells were analyzed on a FACSCanto II ﬂow cytometer (BD Biosciences,
USA). Data analysis was performed using BD FACSDiva™ software (BD
Biosciences).
2.7. Measurement of cytokine production by T cells in thoracic lymph nodes
after restimulation with anti-CD3 antibody in vitro
In order to examine speciﬁc T cell responses, after mice were
sacriﬁced on day 56, lung-draining lymph nodes were collected from
the thorax and transferred to cold sterile PBS. Single cell suspensions
of the thoracic lymph nodes (TLNs) were made using a 70 μm nylon
cell strainer (BD Biosciences) and rinsed with 15 mL of PBS. The cells
were washed and resuspended in RPMI 1640 culture medium without
L-glutamine and phenol red (Lonza) supplemented with 10% heat-
inactivated fetal calf serum (FCS, HyClone Laboratories, USA) and 0.1%
penicillin–streptomycin solution (pen–strep, Sigma). The total number
of cells isolated from whole suspension of TLNs was determined using
a Beckman Z1 coulter® Particle Counter (Beckman, USA). TLN cells
(4 × 106 cells/mL; 100 μL/well) were cultured in a Greiner bio-one
CellSTAR 96-well U-bottom plate (Greiner Bio-One B.V., Alphen a/d
Rijn, The Netherlands) in a medium with or without O/N pre-
coating of the wells with 50 μg/mL of anti-CD3 antibody (Bioceros
B.V., Utrecht, The Netherlands). The supernatant was harvested
after 5 days of culture at 37 °C in 5% CO2 and stored at−20 °C until
further analysis.
The levels of cytokines in the supernatant were measured by ﬂow
cytometry using a BD™ Cytometric Bead Array (CBA) Mouse Th1/Th2/
Th17 Cytokine kit (BD Biosciences) according to manufacturer's
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ysis was performed using BD FCAP Array™ v3.0.1 Software (BD
Biosciences).
2.8. Measurement of mouse mast cell protease 1 levels in serum and BAL
ﬂuid
To assess mast cell activation, after mice were sacriﬁced on day 56,
blood samples were collected from mice by cardiac puncture. The
blood was coagulated for 1 h at room temperature and subsequently
centrifuged for 5 min at 17,500 g. BAL ﬂuid samples were collected as
described previously in this section. Serum and BAL ﬂuid samples
were stored at−80 °C until further analysis.
Mouse mast cell protease 1 (mMCP-1) protein expression levels in
serum and BAL ﬂuid were determined by enzyme-linked immunosor-
bent assay (ELISA) using the Mouse MCPT-1 (mMCP-1) ELISA Ready-
SET-Go!® kit (eBioscience) according to manufacturer's protocol.
2.9. Histology and immunohistochemistry
After mice were sacriﬁced on day 56, lungs were ﬁxed with 10% for-
malin infusion through a tracheal cannula at a constant pressure of
25 cm H2O. The lungs were immersed in ﬁxative for at least 24 h, after
which the left lung was embedded in parafﬁn. After parafﬁn embed-
ding, 5 μm sections were cut and deparafﬁn sections were ﬁrst
deparafﬁnized. Endogenous peroxidase activity was blocked with 0.3%
H2O2 (Merck) in methanol for 30 min at room temperature and
rehydrated in a graded ethanol series to PBS and parafﬁn section wereFig. 2. Total and differential BAL ﬂuid cell counts. Pulmonary inﬂammation represented by the in
ages of the total cell count for each group (A). Mice in all groups were sensitizedwith OVA. OVA
the OVA/Sal–PBS and OVA/OVA–PBS groups received PBS as treatment, mice in the OVA/Sal–Bb
AOS. Results are shown as mean ± SEM, n = 6 mice/group, for one independent experiment. S
parison test after one-wayANOVA. #Statistically signiﬁcant difference (p b 0.05) compared to O
mice.stained with hematoxylin/eosin (H&E) for inﬂammation, periodic
acid-schiff (PAS) for goblet cells, Masson's trichrome for connective tis-
sue, rabbit polyclonal anti-α-smooth muscle actin antibody (Abcam,
Cambridge, UK) for smooth muscle cells and rabbit polyclonal anti-
Ki76 antibody (Abcam) for proliferating cells according to standard
methods.
Photomicrographs were taken with an Olympus BX50 microscope
equipped with a Leica DFC 320 digital Camera.
Slides were reviewed in blinded fashion by two independent ob-
servers and were scored as 0 to 5 (no to abundant staining).
2.10. Statistical analysis
Data analysis was performed using a 1-way analysis of variance
(one-way ANOVA) with the Bonferroni's post-hoc test. All statistical
analyses were performed using GraphPad Prism software program
(GraphPad Prism software version 5.03).
3. Results
3.1. Bb/scFOS/lcFOS/AOS treatment reduces pulmonary airway inﬂamma-
tion in chronic asthmatic mice
To study the extent of airway inﬂammation in the asthmatic mice
after treatment with Bb/scFOS/lcFOS/AOS, BAL ﬂuid was examined
for leukocyte accumulation (Fig. 2). The total inﬂammatory cell
number in the BAL ﬂuid of OVA/OVA–PBS mice was signiﬁcantly in-
creased (Fig. 2A), which was due to a relative increase in the numberﬂux of speciﬁc leukocytes in BAL ﬂuid (B–E). Differential cell counts are shown as percent-
/Sal mice were challengedwith saline. OVA/OVAmice were challenged with OVA. Mice in
/scFOS/lcFOS/AOS and OVA/OVA–Bb/scFOS/lcFOS/AOSwere treated with Bb/scFOS/lcFOS/
tatistical signiﬁcance of differences was tested using post-hoc Bonferroni's multiple com-
VA/Sal–PBSmice. ¤Statistically signiﬁcant difference (p b 0.05) compared to OVA/OVA–PBS
Fig. 3. Relative TLR and NLRmRNA expression inmouse whole lung tissue during chronic asthma. The bars indicate themin to max values and the line represents themean, n= 6mice/
group, of the TLR andNLRmRNAexpression levels inOVA-sensitized, saline-challenged (OVA/Sal,white bars)mice andOVA-sensitized, OVA-challenged (OVA/OVA, gray bars)mice treat-
edwith PBS or Bb/scFOS/lcFOS/AOS. Data is shown for one independent experiment. The results are presented asmRNA expression levels relative to levels found in the OVA/Sal–PBSmice.
Statistical signiﬁcance of differences was tested using post-hoc Bonferroni's multiple comparison test after one-way ANOVA. #Statistically signiﬁcant difference (p b 0.05) compared to
OVA/Sal–PBS mice. ¤Statistically signiﬁcant difference (p b 0.05) compared to OVA/OVA–PBS mice.
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Sal–PBS mice. The relative number of macrophages was signiﬁcantly
decreased in OVA/OVA–PBS mice as compared to the OVA/Sal–PBS
group (Fig. 2D). Bb/scFOS/lcFOS/AOS treatment, however, signiﬁ-
cantly reduced the total number of inﬂammatory cells (Fig. 2A) and
relative number of eosinophils (Fig. 2B) as compared to OVA/OVA–
PBS mice. The relative numbers of neutrophils, macrophages and
lymphocytes (Fig. 2C, D and E) remained unchanged.
3.2. Bb/scFOS/lcFOS/AOS treatment modulates PRR mRNA expression in
lung tissue of chronic asthmatic mice
To investigate whether PRRs are involved in the ongoing chronic in-
ﬂammation during asthma, themRNA expression of Tlr1–9 and Nod1–2
in lung tissue was measured (Fig. 3). The mRNA expression of Tlr3, Tlr9
and Nod1 was signiﬁcantly decreased in OVA/OVA–PBS mice as com-
pared to the OVA/Sal–PBS group (Fig. 3A). Interestingly, Bb/scFOS/
lcFOS/AOS treatment prevented the decrease inTlr3, Tlr9 and Nod1 ex-
pression (Fig. 3B). In non-asthmatic controls, the expression of Tlr9Fig. 4. Relative cytokinemRNA expression inmousewhole lung tissue during chronic asthma. Th
of the cytokinemRNA expression levels inOVA-sensitized, saline-challenged (OVA/Sal,white ba
or Bb/scFOS/lcFOS/AOS. Data is shown for one independent experiment. The results are presen
ferences was tested using post-hoc Bonferroni's multiple comparison test after one-way A
¤Statistically signiﬁcant difference (p b 0.05) compared to OVA/OVA–PBS mice.was signiﬁcantly decreased in the OVA/Sal–Bb/scFOS/lcFOS/AOS group
as compared to OVA/Sal–PBS mice; yet, the expression of the other
PRRs in non-asthmatic controls remained unchanged (Fig. 3B).3.3. Bb/scFOS/lcFOS/AOS treatmentmodulates cytokinemRNA expression in
lung tissue of chronic asthmatic mice
To gauge the extent of inﬂammation and the Th response in the
lung, the mRNA expression of various cytokines was measured
(Fig. 4). The mRNA expression of Il1β, Il6 and Il17 was signiﬁcantly
increased and Il5 was signiﬁcantly decreased in OVA/OVA–PBS
mice as compared to the OVA/Sal–PBS group (Fig. 4A). Bb/scFOS/
lcFOS/AOS treatment, however, signiﬁcantly decreased Il1β, Il6, Il12
and Tnfα and signiﬁcantly increased Il10 and Il23 expression in
OVA/OVA mice as compared to the OVA/OVA–PBS group (Fig. 4B).
Additionally, the expression of Il17 tended to be decreased in OVA/
OVA–Bb/scFOS/lcFOS/AOS mice when compared to the OVA/OVA–
PBS group.e bars indicate themin tomax values and the line represents themean, n=6mice/group,
rs)mice andOVA-sensitized, OVA-challenged (OVA/OVA, gray bars)mice treatedwith PBS
ted as mRNA expression levels relative to OVA/Sal–PBS mice. Statistical signiﬁcance of dif-
NOVA. #Statistically signiﬁcant difference (p b 0.05) compared to OVA/Sal–PBS mice.
Fig. 5. Relative T cell transcription factor mRNA expression in mouse whole lung tissue during chronic asthma. The bars indicate the min to max values and the line represents the mean,
n = 6 mice/group, of the transcription factor mRNA expression levels in OVA-sensitized, saline-challenged (OVA/Sal, white bars) mice and OVA-sensitized, OVA-challenged (OVA/OVA,
gray bars) mice treated with PBS or Bb/scFOS/lcFOS/AOS. Data is shown for one independent experiment. The results are presented as mRNA expression levels relative to OVA/Sal–PBS
mice. Statistical signiﬁcance of differences was tested using post-hoc Bonferroni'smultiple comparison test after one-way ANOVA. #Statistically signiﬁcant difference (p b 0.05) compared
to OVA/Sal–PBS mice. ¤Statistically signiﬁcant difference (p b 0.05) compared to OVA/OVA–PBS mice.
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the immune response away from Th2 towards Treg in the lungs of chronic
asthmatic mice
To further explore the effects of Bb/scFOS/lcFOS/AOS on Th and
Treg responses and skewing in the lung, the mRNA expression of
Th- and Treg-speciﬁc transcription factors wasmeasured (Fig. 5). Ra-
tios for Gata3/Tbet (Th2/Th1), Foxp3/Rorγt (Treg/Th17), Foxp3/Gata3
(Treg/Th2) and Foxp3/Tbet (Treg/Th1) mRNA expression were also
calculated (Table 1). The mRNA expression of Th1-(Tbet) and Treg-
(Foxp3) transcription factors was signiﬁcantly decreased in OVA/
OVA–PBS mice as compared to the OVA/Sal–PBS group (Fig. 5A).
The expression of Th2-(Gata3), and Th17-(Rorγt) transcription fac-
tors remained unchanged (Fig. 5A). The Gata3/Tbet ratio, however,
was signiﬁcantly increased and Foxp3/Rorγt and Foxp3/Gata3 ratios
were signiﬁcantly decreased in OVA/OVA–PBS mice as compared to
the OVA/Sal–PBS group (Table 1). After treatment with the Bb/
scFOS/lcFOS/AOS, OVA/OVA mice showed a signiﬁcant increase in
the expression of Foxp3 as compared to the OVA/OVA–PBS group
(Fig. 5B) which led to signiﬁcant increases in the Foxp3/Rorγt and
Foxp3/Gata3 ratios (Table 1).Table 1
Effect of Bb/scFOS/lcFOS/AOS treatment on T helper cell balance in whole lung tissue.
Treatment Ratio OVA/Sal OVA/OVA
Mean ratio SEM Mean ratio SEM
PBS Gata3/Tbet 1.03 0.10 1.66⁎ 0.37
Foxp3/Roryt 0.82 0.09 0.29⁎ 0.20
Foxp3/Gata3 0.83 0.09 0.41⁎ 0.28
Foxp3/Tbet 0.86 0.09 0.69 0.47
Bb/scFOS/IsFOS/AOS Gata3/Tbet 1.09 0.12 1.11 0.09
Foxp3/Roryt 1.01 0.05 1.49⁎⁎ 0.10
Foxp3/Gata3 1.01 0.05 1.20⁎⁎ 0.08
Foxp3/Tbet 1.10 0.06 1.21 0.08
Ratios for Gata3/Tbet (Th2/Th1), Foxp3/Rorγt (Treg/Th17), Foxp3/Gata3 (Treg/Th2) and
Foxp3/Tbet (Treg/Th1) mRNA expression in whole lung tissue are shown for OVA/Sal
and OVA/OVA mice for each treatment. Data is represented as mean ratio ± SEM, n = 6
mice/group. The mean ratio was calculated by dividing the individual expression values
for the ﬁrst transcription factor (numerator) by the mean expression value for the
second transcription factor (denominator). Statistical signiﬁcance of differences was
tested using post-hoc Bonferroni's multiple comparison test after one-way ANOVA.
⁎ Statistically signiﬁcant difference (p b 0.05) compared to the OVA/Sal–PBS group.
⁎⁎ Statistically signiﬁcant difference (p b 0.05) compared to the OVA/OVA–PBS group.3.5. Bb/scFOS/lcFOS/AOS treatment increases Foxp3 protein expression in
blood CD4+CD25+Foxp3+ T cells of chronic asthmatic mice
In order to determine if the transcriptional changes induced in
Foxp3 expression could be found at a protein expression level, ﬂow
cytometry was used to examine Foxp3 protein expression in Treg
cells in the blood of mice (Fig. 6). Treg cells were identiﬁed as
CD4+CD25+Foxp3+ cells (Fig. 6A) and the magnitude of Foxp3
protein expression on each cell was determined by examining the
percent of cells that are CD4+CD25+Foxp3+ (Fig. 6B) and the
mean ﬂuorescence intensity (MFI) of the Foxp3 staining (Fig. 6C).
The percentage of CD4+CD25+Foxp3+ regulatory T cells was not
signiﬁcantly different between the groups. However, Bb/scFOS/
lcFOS/AOS treatment increased Foxp3 protein expression in the
blood Treg cells. The staining intensity of Foxp3 on day 56was signif-
icantly higher in OVA/OVA–Bb/scFOS/lcFOS/AOS mice as compared
to the OVA/OVA–PBS group. The staining intensity of Foxp3 on day
0 (before sensitization, challenge and treatment) did not differ
among the different groups (data not shown).
3.6. Bb/scFOS/lcFOS/AOS treatment reduces T cell activity in chronic asth-
matic mice
To investigate the effect of Bb/scFOS/lcFOS/AOS treatment on cyto-
kine production by T cells in lung draining lymph nodes, TLN-cell cul-
tures were stimulated with anti-CD3, a pan T cell stimulator, and the
cytokine levels in the supernatant were measured (Fig. 7). The expres-
sion of IL-2, IL-4, IL-6, TNF-α and IFN-γ was signiﬁcantly increased in
anti-CD3-stimulated TLN cells of OVA/OVA–PBS mice as compared to
samples from the OVA/Sal–PBS group. Bb/scFOS/lcFOS/AOS treatment,
however, signiﬁcantly decreased the expression of IL-2, IL-6, TNF-α
and IFN-γ in anti-CD3-stimulated TLNs of OVA/OVA mice as compared
to the OVA/OVA–PBS group. No differences in cytokine expression
were observed in OVA-stimulated TLN cells in the different groups
(data not shown).
3.7. Bb/scFOS/lcFOS/AOS treatment inhibits mucosal mast cell
degranulation in chronic asthmatic mice
To examine the effect of Bb/scFOS/lcFOS/AOS treatment on mast
cell activity, enzyme-linked immunosorbent assay was employed
to measure mMCP-1 protein levels in serum and BAL ﬂuid. The expres-
sion of mMCP-1 was more than doubled in serum of OVA/OVA–PBS
Fig. 6. Effect of Bb/scFOS/lcFOS/AOS treatment on Foxp3 protein expression levels in Treg cells during chronic asthma. T cells were isolated on day 56 from whole blood of OVA/Sal and
OVA/OVA mice, treated with PBS or Bb/scFOS/lcFOS/AOS. (A) Representative dot plots of T cells analysis in the blood. T cells were gated based on FSC–SSC pattern, followed by analysis
of expression of CD4. Then co-expression of Foxp3 and CD25 (regulatory T cells; Treg) was analyzed. (B) Percentage of CD4+CD25+Foxp3hi cells. (C) Mean ﬂuorescence intensity
(MFI) of Foxp3 on Treg cells relative to the OVA/Sal–PBS group (white bar). Data is shown as mean ± SEM, n = 6 mice/group, for one independent experiment. Statistical signiﬁcance
of differenceswas tested using post-hoc Bonferroni'smultiple comparison test after one-way ANOVA. ¤Statistically signiﬁcant difference (p b 0.05) compared to theOVA/OVA–PBS group.
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OVA/Sal–PBS group (0.5 μg/mL ± 0.20; n = 5). Interestingly,
Bb/scFOS/lcFOS/AOS treatment reduced mMCP-1 levels by more than
80% in OVA/OVA mice (0.08 μg/mL ± 0.02; n = 5; p b 0.0001). Similar
results were observed in the BAL ﬂuid; mMCP-1 levels were more than
50% reduced in OVA/OVA–Bb/scFOS/lcFOS/AOS mice (402.3 pg/mL ±
141.5; n = 6; p b 0.05) as compared to the OVA/OVA–PBS group
(980.9 pg/mL ± 208.5; n = 6).
3.8. Bb/scFOS/lcFOS/AOS treatment reduces airway remodeling features in
chronic asthmatic mice
In order to examine the effect of Bb/scFOS/lcFOS/AOS treatment on
airway remodeling, semi-quantitative histological and immunohisto-
chemical analyses of lung tissue were performed (Fig. 8). In the lung
sections of OVA/OVA–PBS mice, increased inﬂammation score and
number of goblet cells, collagenous connective tissue ﬁbers, airway
smooth muscle cells and proliferating cells was observed as comparedto the OVA/Sal–PBS group. Bb/scFOS/lcFOS/AOS treatment, however, re-
duced inﬂammation in the lungs of OVA/OVA–Bb/scFOS/lcFOS/AOS
mice and decreased the number of collagenous connective tissue ﬁbers
and proliferating cells as compared to the OVA/OVA–PBS group.
4. Discussion and conclusions
Non-digestible oligosaccharides were shown to directly interact
with the epithelium and to modulate the intestinal mucosal and sys-
temic immune system from an allergic tuning towards a Treg and Th1
setting [49]. Additionally, previous studies have demonstrated that
combination of B. breve M-16V with a mixture of short- and long-
chain non-digestible oligosaccharides is more effective at reducing the
allergic response in mice than non-digestible oligosaccharides alone
[18].
The aim of this study was to investigate the therapeutic effects of
long-term treatment with a combination of B. breve with a speciﬁc
mixture of non-digestible oligosaccharides (Bb/scFOS/lcFOS/AOS) on
Fig. 7. Cytokine levels after TLN T cell stimulation. Thoracic lymph nodes (TLNs) were isolated frommice on day 56 and restimulated in vitrowith plate-bound anti-CD3 antibody or me-
dium only for 5 days (37 °C, 5% CO2). Data is shown as mean of cytokine concentration (pg/mL) ± SEM, n = 6 mice/group, for one independent experiment. Statistical signiﬁcance of
differences was tested using post-hoc Bonferroni's multiple comparison test after one-way ANOVA. #Statistically signiﬁcant difference (p b 0.05) compared to the OVA/Sal–PBS group.
¤Statistically signiﬁcant difference (p b 0.05) compared to the OVA/OVA–PBS group.
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rine model of chronic asthma. The total inﬂammatory cell number and
BAL ﬂuid eosinophil and neutrophil counts were signiﬁcantly increased
in OVA/OVA–PBS mice as compared to the OVA/Sal–PBS group. Addi-
tionally, increased number of inﬂammatory cells and goblet cells, collag-
enous connective tissue ﬁbers, airway smooth muscle cells and
proliferating cells was observed in lung sections of OVA–OVA–PBS
mice. Hence, our model mimics the airway inﬂammation and remodel-
ing found in chronic asthma [1]. Bb/scFOS/lcFOS/AOS treatment signiﬁ-
cantly reduced the total number of inﬂammatory cells and BAL ﬂuid
eosinophil counts; reduced the inﬂammation; and decreased the num-
ber of collagenous connective tissue ﬁbers and proliferating cells in the
lungs of sensitized and challenged mice. To our knowledge, we demon-
strate here for the ﬁrst time that Bb/scFOS/lcFOS/AOS treatment is effec-
tive at reducing chronic allergic inﬂammation by attenuating the total
inﬂammatory cell number, particularly eosinophil counts in the BAL
ﬂuid; and airway remodeling.
PRRs are key components of the innate immunity of which the func-
tion and expression are associated with susceptibility towards allergic
asthma. The mRNA expression of Tlr3, Tlr9 and Nod1 was signiﬁcantly
decreased in the lungs of OVA/OVA–PBS mice. Viral activation of Tlr3
was reported to play a critical role in exacerbation of respiratory dis-
eases in mice, including asthma [41]. However, no direct associations
between Tlr3 expression and function with asthma have been reported
yet, and whether the decreased mRNA expression of Tlr3 caused by thechronic inﬂammatory status of the animals is pro-inﬂammatory or anti-
inﬂammatory is unknown. Single nucleotide polymorphisms in the
Nod1 gene that affected microbial recognition are positively associated
with susceptibility towards asthma in farming children [34–36]; yet,
the link between the decreased mRNA expression of Nod1 observed in
this current study, and the inﬂammatory status of the animals remains
to be elucidated. TLR9 has been shown to exert its immunomodulatory
effects on asthma by skewing the increased Th2/Th1 cell balance to-
wards Th1 cell [38–40]. Bb/scFOS/lcFOS/AOS treatment normalized the
expression levels of Tlr3 andNod1. Importantly, Tlr9 expressionwas sig-
niﬁcantly increased in OVA/OVA mice treated with Bb/scFOS/lcFOS/
AOS.
Th2 cells play a major role in allergic asthma, and Th1/Th2 imbal-
ances as well as disturbed Th17/Treg balances were found in asthmatic
patients [44]. Th2 dominancewas observed in the OVA/OVA–PBS group
represented by high Gata3/Tbet and low Foxp3/Gata3 ratios. Additional-
ly, a signiﬁcant decrease in Th1 and Treg transcription factor mRNA ex-
pression, and low Foxp3/Rorγt ratio were found. Hence, our model
mimics the Th2-responses found in chronic asthma [1]. Interestingly,
Bb/scFOS/lcFOS/AOS treatment shifted the immune balance towards
Treg, with signiﬁcantly increased Foxp3/Rorγt and Foxp3/Gata3 ratios
compared to the OVA/OVA–PBS group.More importantly, the above ob-
served effects of the Bb/scFOS/lcFOS/AOS on the Th and Treg responses
in the lung are conﬁrmed by the detection of high Foxp3-expressing
Tregs in the blood of treated animals. Treg cells play a key role in
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Fig. 8. Effect of Bb/scFOS/lcFOS/AOS treatment on airway remodeling during chronic asthma. (A) Representative photomicrographs for 5 mice/group, for one independent experiment, of
histological and immunohistochemical staining for inﬂammation (hematoxylin–eosin, HE, I); goblet cells (periodic acid Schiff, PAS, II); connective tissue (Masson trichrome,Masson, III);
anti-α-smooth muscle actin (α-smooth muscle, IV) and proliferating cells (anti-Ki67, V) in lung tissue of OVA/Sal–PBS mice (A), OVA/OVA–PBS mice (B), OVA/Sal–Bb/scFOS/lcFOS/AOS
mice (C) and OVA/OVA–Bb/scFOS/lcFOS/AOS (D). Original magniﬁcation key ﬁgures 100×, original magniﬁcation boxes 200×. (B) Compiled data of semi-quantitatively graded histology
and immunohistochemistry. Slides were reviewed in blinded fashion by two observers independently and slides were scored as 0 to 5 (no to abundant staining). Results are shown as
mean score ± SEM of n = 5 mice/group.
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creased expression of Foxp3 in Tregs is directly associated with in-
creased suppressive function of these cells [43,50].
Expression of the cytokines Il1β, Il6 and Il17 was signiﬁcantly in-
creased in OVA/OVA–PBS mice and expression of the Th2 cytokine Il5
was signiﬁcantly decreased. These four cytokines have been reported
to enhance asthma and increased levels of Il1β, Il6 and Il17 are found
in the sputum and BAL ﬂuid of individuals with asthma [30]. A reason-
able explanation for the decrease in Il5 mRNA expression remains to
be elucidated as mRNA levels do not always reﬂect protein synthesis.
Accordingly, no increase in Gata3mRNA expression in lung tissue was
observed. Bb/scFOS/lcFOS/AOS treatment, however, signiﬁcantly de-
creased the expression of the pro-inﬂammatory cytokines Il1β, Il6 and
Tnfα, restoring them to normal levels and also decreased Il12. Addition-
ally, the expression of Il10 and Il23 was signiﬁcantly increased. It has
been reported that IL-12 is involved in the differentiation of Th1 cells.
The decrease in Il12 might be due to the increased expression of the
anti-inﬂammatory cytokine Il10, as IL-10 is known to inhibit Il12 p40
transcription [30,51]. Interestingly, the observed effects of the Bb/
scFOS/lcFOS/AOS treatment on cytokine expression in the lung are con-
ﬁrmed by cytokine levels in the TLNs. Bb/scFOS/lcFOS/AOS treatment
signiﬁcantly decreased the production of IL-2, IL-6 and TNF-α, restoring
them to normal levels, and IFN-γ by T cells in the TLNs of OVA/OVAmice
after a speciﬁc activation with an anti-CD3 antibody in vitro. In summa-
ry, although the expression of Rorγt was not increased, a predominant
Th17 immunity in chronically asthmatic mice is observed with a less
prominent role of Th2 immunity. These ﬁndings are in accordance
with other animal and human studies in which the number of Th17
cells and the concentration of related cytokines were associated with
asthma severity [52]. Bb/scFOS/lcFOS/AOS treatment, however, induced
a strong anti-inﬂammatory response represented by the upregulation of
Foxp3 and Il10, and suppression of pro-inﬂammatory cytokine
expression.
Mast cells play a central role in both the early phase and late phase of
allergen-induced airway inﬂammation [6]. Intriguingly, Bb/scFOS/
lcFOS/AOS treatment was effective at inhibiting mucosal mast cell de-
granulation, as shown by the signiﬁcant decrease in the protein levels
of mMCP-1 systemically, in serum, as well as in the BAL ﬂuid of treated
mice. Themechanismbywhich Bb/scFOS/lcFOS/AOS treatment reduced
mast cell degranulation still needs further investigation. Possibly, these
ﬁndings might be explained by the induction of galectins by the Bb/
scFOS/lcFOS/AOS mixture. Recently, a combination of B. breve M-16V
with non-digestible oligosaccharides, although with a different oligo-
saccharide composition, was shown to induce galectin-9. The latter in
turn suppressed allergic symptoms, including mast cell degranulation,
in mice and humans [49]. Additionally, immune challenge in the air-
ways might promote the trafﬁcking of Treg cells, activated in the intes-
tine, to the respiratory mucosa where they induce protective and anti-
inﬂammatory responses as described in [53].
To our knowledge, this is the ﬁrst report inwhich the therapeutic ef-
fects of long-term treatment with Bb/scFOS/lcFOS/AOS combination, on
inﬂammatory response and airway remodeling are investigated in a
murine OVA-induced chronic asthma model. We show here that Bb/
scFOS/lcFOS/AOS treatment was effective at reducing pulmonary air-
way inﬂammation; modulating the mRNA expression of PRRs, T
helper-speciﬁc cytokines and transcription factors; as well as reducing
airway remodeling. More importantly, Bb/scFOS/lcFOS/AOS treatment
was a potent inducer of regulatory responses; increasing Il10 and
Foxp3 transcription in lung tissue and augmenting protein expression
of Foxp3 in blood Treg cells. Additionally, Bb/scFOS/lcFOS/AOS treat-
ment reduced T cell cytokine production and inhibitedmast cell degran-
ulation. Our current ﬁndings show that this speciﬁc combination of
B. breve with non-digestible oligosaccharides may be beneﬁcial in the
management of chronic inﬂammation in allergic asthma.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.01.005.Conﬂict of interest
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